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Abstract
Background: The Frail-VIG frailty index has been developed recently. It is an instrument with a multidimensional
approach and a pragmatic purpose that allows rapid and efficient assessment of the degree of frailty in the context
of clinical practice. Our aim was to investigate the convergent and discriminative validity of the Frail-VIG frailty
index with regard to EQ-5D-3L value.
Methods: We carried out a cross-sectional study in two Primary Health Care (PHC) centres of the Catalan Institute
of Health (Institut Català de la Salut), Barcelona (Spain) from February 2017 to January 2019. Participants in the study
were all people included under a home care programme during the study period. No exclusion criteria were
applied. We used the EQ-5D-3L to measure Health-Related Quality of Life (HRQoL) and the Frail-VIG index to
measure frailty. Trained PHC nurses administered both instruments during face-to-face assessments in a participant’s
home during usual care. The relationships between both instruments were examined using Pearson’s correlation
coefficient and multiple linear regression analyses.
Results: Four hundred and twelve participants were included in this study. Frail-VIG score and EQ-5D-3L value were
negatively correlated (r = − 0.510; P < 0.001). Non-frail people reported a substantially better HRQoL than people
with moderate and severe frailty. EQ-5D-3L value declined significantly as the Frail-VIG index score increased.
Conclusions: Frail-VIG index demonstrated a convergent validity with the EQ-5D-3L value. Its discriminative validity
was optimal, as their scores showed an excellent capacity to differentiate between people with better and worse
HRQoL. These findings provide additional pieces of evidence for construct validity of the Frail-VIG index.
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Background
Validity is defined as “the degree to which an instrument
truly measures the construct(s) it purports to measures”
[1]. Validation is a continuous process and different
forms of validation can be applied. Criterion validity and
construct validity are two types of validity. Criterion
validity is applicable when there is the gold standard for
the construct that is measured, it refers to the degree to
which the scores of a measurement instrument are an
adequate reflection of a gold standard [1, 2]. By contrast,
construct validity is applicable when there is no gold
standard, it refers to the degree to which the scores of a
measurement instrument are consistent with the avail-
able knowledge about the construct [1, 2].
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On the other hand, frailty is defined as “a clinical state
in which there is an increase in an individual’s vulner-
ability to develop negative health-related events (includ-
ing disability, hospitalizations, institutionalizations, and
death) when exposed to endogenous or exogenous
stressors” [3]. It is a complex and multidimensional con-
cept for which there are numerous and multiple oper-
ational definitions. This fact has contributed to the lack
of an accepted gold standard [3, 4]. As a result, most
frailty measurement instruments assess their validity by
analysing the degree of consistency of their scores with
different hypotheses about their relationship with other
instruments or the differences between relevant groups.
In other words, hypothesis testing for construct validity
studies is carried out because of the difficulty in asses-
sing criterion validity.
A new frailty index, the Frail-VIG index, has been
developed recently [5, 6]. It is an instrument with a
multidimensional approach and a pragmatic purpose
that allows rapid and efficient assessment of the degree
of frailty in the context of clinical practice. This meas-
urement instrument has shown to have an optimal
capacity to predict two-year mortality (Area Under
Curve 0.85) [6]. The relationship of their scores with
those of the Clinical Frailty Scale [7] has been evaluated
in a cross-sectional study and a strong positive correl-
ation (r = 0.706) has been established [8]. All of these
studies have been conducted in an inpatient hospital
setting and there have been no studies in primary health
care (PHC) settings.
Previous research suggests an association between frailty
and worse quality of life, but its findings are mixed and in-
consistent. However, recent systematic reviews show a
consistent negative association between frailty and quality
of life among community-dwelling people [9, 10]. Besides,
the validity of a measuring instrument does not reside in
the instrument itself but in how it is used and hence de-
pends on its appropriateness to the target population and
the specific context of administration [2]. Therefore, a
good approach to further developing evidence of the valid-
ity of the Frail-VIG index would mean to analyse the rela-
tionship of its scores with those of another instrument
that measures the quality of life (both instruments admin-
istered in the context of PHC).
Consequently, we carried out this study in a PHC set-
ting to investigate the convergent and discriminative val-
idity of the Frail-VIG index regard to health-related
quality of life (HRQoL) measured by the EQ-5D three-
level version (EQ-5D-3L). Concerning convergent valid-
ity, we hypothesised that the relationship of scores be-
tween instruments was moderate to strong and negative.
With regard to discriminative validity, we hypothesised
that non-frail people would have higher scores on
HRQoL than frail people.
Methods
Study design
We conducted a cross-sectional study on measurement
properties.
Setting and participants
The study was carried out in two PHC centres of the
Catalan Institute of Health (Institut Català de la Salut),
Barcelona (Spain) from February 2017 to January 2019.
In these centres, people who cannot visit the centre for
PHC services are included under a home care
programme and are cared at-home by PHC centre’s pro-
fessionals. Participants in the study were all people in-
cluded under a home care program during the study
period. No exclusion criteria were applied.
Variables and data measurements
We used the EQ-5D-3L to measure HRQoL which is
one of the most widely used measurement instruments
[11–13]. It is a generic measurement instrument because
it measures HRQoL in a way that can be used across dif-
ferent types of patients, health conditions, and treat-
ments. This instrument comprises two parts. The first
part consists of five dimensions: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. Each
dimension has three levels: no problems, some problems,
and extreme problems. Unique health status is defined
by combining a level of each of the five dimensions
resulting in a five-digit number, with 11,111 reflecting
the best possible health status and 33,333 the worst. The
second part of the instrument is the EQ VAS which
comprises a visual analogue scale from 0 (the worst
health imaginable) to 100 (the best health imaginable).
EQ-5D-3L is designed for self-completion by respon-
dents, but several other modes of administration (inter-
view administered, face-to-face interview, or telephone
interview) are also possible. Existing research has estab-
lished that self-completion and assisted completion pro-
duce equivalent scores overall and therefore both
methods can be used [14, 15]. For the present study we
used the Spanish face-to-face interview version as a large
majority of the participants were unable to read and
write [16].
Frailty was measured using the original Spanish version
of Frail-VIG index. It is composed of 22 items that evalu-
ate 25 deficits based on the comprehensive geriatric as-
sessment [5, 6]. It is constructed using only variables
recorded during the usual clinical evaluation process. The
value of the index is obtained from the sum of the identi-
fied deficits divided by 25, the total number of potential
deficits, so the higher the presence of deficits the higher
the score in the index. Likewise, different index cut-off
points have been established that distinguish between four
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Table 1 General characteristics of participants overall and by frailty states. Values are absolute frequencies (percentages) unless
stated otherwise






















Age, mean (SD) 88.0 (8.1) 86.7 (8.0) 88.8 (7.4) 88.1 (8.2) 86.8 (8.8)
Female 282 (68,4) 9 (75.0) 81 (69.8) 126 (66.0) 66 (71.0)
Health-related quality of life EQ-5D-3L value, mean (SD) 0.30 (0.23) 0.48 (0.19) 0.42 (0.20) 0.29 (0.22) 0.13 (0.15)




Needs help managing financial matters (bank, shops,
or restaurants)
350 (85.0) 5 (41.7) 79 (68.1) 173 (90.6) 93 (100.0)
IADLs:
Telephone use




Needs assistance in preparing or administering
medications
304 (73.8) 0 (0.0) 51 (44.0) 161 (84.3) 92 (98.9)
ADLs: Barthel
index (BI)
No dependency (BI > = 95) 6 (1.5) 1 (8.3) 3 (2.6) 2 (1.0) 0 (0.0)
Mild-moderate dependency (BI from 90 to 65) 143 (34.7) 11 (91.7) 79 (68.1) 51 (26.7) 2 (2.2)
Moderate-severe dependency (BI from 60 to 25) 175 (42.5) 0 (0.0) 33 (28.4) 111 (58.1) 31 (33.3)
Absolute dependency (BI <=20) 88 (21.4) 0 (0.0) 1 (0.9) 27 (14.1) 60 (64.5)
Nutritional domain





No cognitive impairment 198 (48.1) 12 (100.0) 90 (77.6) 86 (45.0) 10 (10.8)
Mild-moderate cognitive impairment (equivalent to
GDS < =5)
171 (41.5) 0 (0.0) 26 (22.4) 93 (48.7) 52 (55.9)
Severe-very severe cognitive impairment (equivalent
to GDS > =6)




Need for antidepressant medication 158 (38.3) 0 (0.0) 25 (21.6) 82 (42.9) 51 (54.8)
Insomnia/
anxiety
Frequent need for benzodiazepines or other psychiatric
drugs with a sedative effect for insomnia/anxiety




Do health care professionals perceive the presence of
social vulnerability?
212 (51.5) 4 (33.3) 69 (59.5) 93 (48.7) 46 (49.5)
Geriatric syndromes
Delirium Presence of delirium and/or behaviour disorder requiring
antipsychotic drugs in the last6 months
119 (28.9) 0 (0.0) 8 (6.9) 48 (25.1) 63 (67.7)
Falls In the last 6 months, ≥2 falls or hospitalization due to a fall. 112 (27.2) 0 (0.0) 21 (18.1) 56 (29.3) 35 (37.6)
Ulcers Presence of ulcer (pressure or vascular, any grade) 85 (20.6) 0 (0.0) 9 (7.8) 39 (20.4) 37 (39.8)
Polypharmacy Taking ≥5 drugs 365 (88.6) 8 (66.7) 91 (78.4) 178 (93.2) 88 (94.6)
Dysphagia Difficulty swallowing when eating or drinking? Presence of
aspiration respiratory infections during the last 6 months?
75 (18.2) 0 (0.0) 2 (1.7) 24 (12.6) 49 (52.7)
Severe symptoms
Pain Need for ≥2 conventional analgesics and/or strong opioids
for pain control
87 (21.1) 3 (25.0) 15 (12.9) 49 (25.7) 20 (21.5)
Dyspnoea Basal dyspnoea impeding the ability to leave the house
and/or opioids are frequently needed
19 (4.6) 0 (0.0) 3 (2.6) 10 (5.2) 6 (6.5)
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degrees of frailty: non-frailty, < 0.20; mild, 0.20 to 0.35;
moderate, 0.36 to 0.50 and severe > 0.50 [6].
Researchers developed an instruction manual for the
administration of instruments. Trained PHC nurses
administered both instruments during face-to-face
assessments in a participant’s home during usual care.
These interviews had an average duration of 30 min. A
pilot test with 20 participants was also carried out to
detect possible problems and to introduce improvement
strategies. After this pilot test, no changes in the
procedure were necessary.
Statistical methods
We applied a scoring algorithm based on the
Spanish population to convert EQ-5D-3L states into
a single summary value [13, 17]. This value is
Table 1 General characteristics of participants overall and by frailty states. Values are absolute frequencies (percentages) unless
stated otherwise (Continued)






















Cancer Active cancer 36 (8.7) 0 (0.0) 4 (3.4) 24 (12.6) 12 (12.9)
Respiratory Presence of any type of chronic respiratory disease (COPD,
restrictive lung disease...)
116 (28.2) 1 (8.3) 23 (19.8) 61 (31.9) 31 (33.3)
Cardiac Presence of any type of chronic heart disease (heart failure,
ischemic cardiomyopathy, arrhythmia
248 (60.2) 2 (16.7) 57 (49.1) 124 (64.9) 65 (69.9)
Neurological Presence of any type of neurodegenerative disease (Parkinson,
ALS...) or a history of stroke (ischemic or haemorrhagic)
151 (36.7) 0 (0.0) 24 (20.7) 75 (39.3) 52 (55.9)
Digestive Presence of any type of chronic digestive disease (chronic liver
disease, cirrhosis, chronic pancreatitis, inflammatory bowel
disease, ...
39 (9.5) 1 (8.3) 8 (6.9) 22 (11.5) 8 (8.6)
Renal Presence of chronic renal failure (GFR < 60) 204 (49.5) 4 (33.3) 57 (49.1) 102 (53.4) 41 (44.1)
ADLs Activities of Daily Living, ALS Amyotrophic lateral sclerosis, COPD Chronic Obstructive Pulmonary Disease, GDS Global deterioration scale, GFR
Glomerular Filtration Rate, IAVDs Instrumental Activities of Daily Living, SD Standard deviation
Table 2 Prevalence of the 10 most frequently observed EQ-ED-3 L profiles and frequency of reporting of the worst possible profile
according to frailty state (these were the 10 profiles of 63.1% (n = 260) of the study population (the most frequent profiles in each of




















33322 62 (15.0) 0 (0.0) 4 (3.4) 24 (12.6) 34 (36.6)
22222 60 (14.6) 1 (8.3) 27 (23.3) 26 (13.6) 6 (6.5)
23322 29 (7.0) 0 (0.0) 2 (1.7) 18 (9.4) 9 (9.7)
22221 23 (5.6) 1 (8.3) 12 (10.3) 9 (4.7) 1 (1.1)
22211 22 (5.3) 1 (8.3) 7 (6.0) 14 (7.3) 0 (0.0)
22212 20 (4.9) 1 (8.3) 6 (5.2) 10 (5.2) 3 (3.2)
33311 13 (3.2) 0 (0.0) 0 (0.0) 9 (4.7) 4 (4.3)
22322 12 (2.9) 0 (0.0) 6 (5.2) 6 (3.1) 0 (0.0)
33321 12 (2.9) 0 (0.0) 0 (0.0) 3 (1.6) 9 (9.7)
21221 7 (1.7) 2 (16.7) 4 (3.4) 1 (0.5) 0 (0.0)
Worst possible
33333 4 (1.0) 0 (0.0) 0 (0.0) 2 (1.0) 2 (2.2)
Each digit of profile label corresponds to one of the five dimensions of the EQ-5D-3L (from left to right): Mobility, Self-Care, Usual activities, Pain and discomfort,
and Anxiety and depression
Level 1, no problems; Level 2, moderate problems, and level 3, extreme problems
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“attached to an EQ-5D profile according to a set of
weights that reflect, on average, people’s preferences
about how good or bad the state is” [18] and ranges
from 1 (full health) to 0 (a state as bad as being
death), although there are negative values for the
value, corresponding to those states of health that
are rated as worse than death. This value is often
used in economic evaluations, but it can also be
used to describe the health of a population or the
severity of disease among patients [19].
We calculated central tendency and dispersion
measures for the quantitative variables. For categor-
ical variables, we estimate absolute and relative
frequencies. The relationships between the Frail-VIG
index and the EQ-5D-3L value were examined using
Pearson’s correlation coefficient and multiple linear
regression analyses. Correlation coefficients of ≤0.29
were considered weak, 0.30–0.49 as low, 0.50–0.69
as moderate, and ≥ 0.70 was considered strong
correlation [20]. To examine whether non-frail
people had higher scores on HRQoL than frail
people, a one-way ANOVA was conducted, with
frailty status as the independent variable and the
EQ-5D-3L value as the dependent variable. We used
the statistical software IBM SPSS Statistics version
24 for all analyses.
Results
Four hundred and twelve participants were included in
this study. Table 1 shows their general characteristics
and frailty status according to the Frail-VIG index
scores.
Table 2 describes the 10 most frequent EQ-ED-3 L
profiles according to frailty status. The worst of these
profiles was most prevalent among people with severe
frailty, while the best was more frequent among non-
frailty people.
Pearson’s correlation coefficient between Frail-VIG
index and EQ-5D-3L value was negative and moderate
(r = −0.510; P < 0.001). After adjusting for age and sex
variables, the multiple linear regression model revealed
that Frail-VIG index independently correlated with EQ-
5D-3L value (B = -0.945; 95% Confidence Interval,
−1.098 to − 0.791; R2 = 0.287). As you can see from
Table 1, non-frail people reported a substantially better
HRQoL than people with moderate and severe frailty
people. Likewise, closer inspection of Table 3 shows that
the EQ-5D-3L value declined significantly as the Frail-
VIG index score increased.
Discussion
In this study, involving people cared at-home by PHC
professionals, we found that the Frail-VIG index demon-
strated convergent validity with the EQ-5D-3L value.
Furthermore, its discriminative validity was optimal, as
their scores showed an excellent capacity to differentiate
between people with better and worse HRQoL.
Consistent with the literature, this research found that
HRQoL and frailty were negatively associated among
community-dwelling older people [9, 10]. Studies on
other cumulative deficit models of frailty have also found
a negative relationship between the frailty state and the
scores of instruments measuring HRQoL, well-being and
life satisfaction [9, 10, 21–23]. However, the results of
this study show that not only is the frailty state associ-
ated with a worse HRQoL but also that there is a linear
association between both indexes (Frail-VIG index and
EQ-5D-3L value). Hypothesis testing is an ongoing
process, so the more hypotheses are tested the more evi-
dence is generated for construct validity [24]. Therefore,
this research supports evidence from previous studies
carried out in the hospital setting on the construct valid-
ity of the Frail-VIG index [6, 8].
This study has several strengths. Most validation
studies of measurement instruments of frailty in
community-dwelling people focus on demonstrating
their predictive potential for adverse outcomes or re-
source use, such as disability, institutionalisation or
hospital admissions [25–27]. In contrast, studies that
analyse their relationship to more positive outcomes
such as HRQoL are less common [10, 28]. Likewise, the
use of the Frail-VIG index in primary care has been
poorly studied, and this is one of the first studies to
analyse its construct validity in this care setting. How-
ever, some limitations exist. The representativeness of
non-frailty people is very low (12 people), probably be-
cause the study population were people in a home-care
programme. A greater representation of this population
might have influenced the Frail-VIG index’s discrimina-
tive validity observed. In addition, we used the EQ-5D
Table 3 EQ-5D-3L value (from “0”, “a state as bad as being
dead” to “1”,“full health”) for the total study population and the
seven groups based on their Frail-VIG score (from “0”, “absence
of frailty” to “1”, “severe frailty”)
EQ-5D-3L value
Frail-VIG index score n Mean (SD) Median (25th–75th)
0–0.15 4 0.55 (0.21) 0.62 (0.32–0.69)
0.16–0.25 50 0.49 (0.17) 0.54 (0.32–0.60)
0.26–0.35 74 0.38 (0.20) 0.49 (0.22–0.54)
0.36–0.45 150 0.31 (0.23) 0.23 (0.12–0.54)
0.46–0.55 72 0.21 (0.20) 0.12 (0.04–0.33)
0.56–065 55 0.12 (0.13) 0.09 (0.04–0.15)
0.66–1 7 0.05 (0.07) 0.04 (0.04–0.12)
Total 412 0.30 (0.23) 0.23 (0.09–0.49)
ANOVA (F = 22.887; degrees of freedom = 6; P < 0.001
EQ-5D-3L value ranged from − 0.08 to 1
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values for this assessment of the measurement proper-
ties of the Frail-VIG index instead of other values such
as the EQ VAS. The EQ VAS can be considered a
measure closer to the patient’s perspective than the
EQ-5D values [29]. Nevertheless, as Devlin and Parkin
point out [19], being able to summarise and represent a
health profile with a single value has important advan-
tages, including simplifying statistical analyses. On the
other hand, both the EQ-5D values and the EQ VAS
are able to discriminate between the quality of life of
most groups of individuals with different socio-
demographic factors, and those with or without clinical
conditions [30]. Furthermore, some studies [31] and
experts in the field of psychometrics [32] report that
older people experience difficulties in understanding
and completing direct estimation methods, such as the
visual analogue scale. For all these reasons, we chose
the EQ-5D values to carry out this psychometric study.
People living with frailty risk experiencing a decline
in their quality of life [9, 10, 33]. The findings of this
study suggest that the interventions aimed at decreas-
ing frailty could have the added benefit of improving
the HRQoL. PHC professionals are naturally posi-
tioned to identify frailty early and to implement inter-
ventions that prevent related adverse effects on the
most vulnerable people [4]. Moreover, the assessment
of frailty in PHC settings requires tools that are not
time consuming as well as valid and reliable which is
way the Frail-VIG index could provide a useful and
appropriate tool for this care setting [34].
Conclusions
This study has identified a negative moderate correlation
between the Frail-VIG index and the EQ-5D-3L values.
It has also shown that the Frail-VIG index was able to
discriminate significantly home-dwelling older people
according to their HRQoL. These findings provide add-
itional pieces of evidence for construct validity of the
Frail-VIG index. Further research is needed on this new
measurement instrument to determine its suitability for
screening and preventing adverse effects of frailty in
PHC settings.
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